As the de­bate over how the US can bet­ter com­pete with Chi­na on drug de­vel­op­ment rolls on, the FDA is de­tail­ing plans for an ex­pe­dit­ed...

A Mass­a­chu­setts fed­er­al judge on Wednes­day ap­proved a $35 mil­lion set­tle­ment be­tween Te­va Phar­ma­ceu­ti­cals and a hand­ful of health­care funds over al­le­ga­tions the com­pa­ny de­layed...

For the sec­ond time this year, a US biotech born out of the pipeline of Chi­na-based Hen­grui Phar­ma­ceu­ti­cals is go­ing pub­lic on the Nas­daq.

Brave­heart...

In­tel­lia Ther­a­peu­tics saidit dis­cov­ered a com­mon link among the pa­tients who faced the high­est liv­er en­zyme el­e­va­tions af­ter re­ceiv­ing its CRISPR gene edit­ing treat­ment...

LifeM­ine Ther­a­peu­tics has hauled in $263 mil­lion across two ven­ture rounds as it seeks to test a po­ten­tial­ly safer, more con­ve­nient im­muno­sup­pres­sant in trans­plant pa­tients...

To broad­en its oph­thal­mol­o­gy port­fo­lio, Tar­sus Phar­ma­ceu­ti­cals is dish­ing out $450 mil­lion up­front to ac­quire Phase 3 biotech Alkeus Phar­ma­ceu­ti­cals, the com­pa­nies said Thurs­day morn­ing.

It's...